The rabbit antibody repertoire, which in the form of polyclonal antibodies has been used in diagnostic applications for decades, would be an attractive source for the generation of therapeutic human antibodies. The humanization of rabbit antibodies, however, has not been reported. Here we use phage display technology to select and humanize antibodies from rabbits that were immunized with human A33 antigen which is a target antigen for the immunotherapy of colon cancer. We first selected rabbit antibodies that bind to a cell surface epitope of human A33 antigen with an affinity in the 1 nM range. For rabbit antibody humanization, we then used a selection strategy that combines grafting of the complementarity determining regions with framework fine tuning. The resulting humanized antibodies were found to retain both high specificity and affinity for human A33 antigen.
The growing significance of antibody-based strategies for the treatment of a variety of diseases demands efficient and reliable routes to human or humanized antibodies with high specificity and affinity. Nonhuman antibodies are highly immunogenic in humans thereby limiting their potential use for therapeutic applications, especially when repeated administration is necessary. In order to reduce their immunogenicity, nonhuman antibodies have been humanized using strategies that are based on rational design, in vitro evolution, or a combination of both. An alternative route is the direct generation of human antibodies from transgenic mice containing human immunoglobulin (Ig) 1 loci or by selection from naive or synthetic human antibody libraries displayed on phage (1, 2).
Here we exploit a new route to humanized antibodies. We use phage display technology to select and humanize antibodies from rabbits that were immunized with a human antigen. Monoclonal antibodies from multiple species are accessible by screening combinatorial antibody libraries displayed on phage (3) . The accessibility of antibody repertoires of multiple species might become substantial in the search for new therapeutic antibodies. In particular the rabbit antibody repertoire, which in the form of polyclonal antibodies has been used in diagnostic applications for decades, would be an attractive source for therapeutic antibodies. The humanization of rabbit antibodies, however, has not been reported.
To allow selective antibody targeting, both high specificity of the antibody and restrictive tissue expression of the antigen are required. For cancer therapy, only a few antibody-antigen systems that meet these requirements have been identified (4) . The A33 system which has been established in clinical trials is one of them (5-7). Mouse monoclonal antibody A33 (5) detects an antigen that is expressed in normal human colon epithelial cells and by Ͼ95% of human colon cancers. Human A33 antigen (8, 9 ) is a transmembrane glycoprotein of the Ig superfamily. It consists of 2 extracellular Ig folds, a single transmembrane domain, and a highly polar intracellular tail containing a Spalmitoylation site. The function of the human A33 antigen in normal and malignant colon tissue is not yet known, however, several properties of the A33 antigen suggested that it is a promising target for immunotherapy of colon cancer (10) . These properties include (i) the highly restricted expression pattern of the A33 antigen, (ii) the expression of large amounts of the A33 antigen on colon cancer cells, (iii) the absence of secreted or shed A33 antigen, (iv) the fact that upon binding of antibody A33 to the A33 antigen, antibody A33 is internalized and sequestered in vesicles, and (v) the good targeting of antibody A33 to A33 antigen expressing colon cancer in preliminary clinical studies. Here we chose the human A33 antigen as a therapeutically relevant target to demonstrate both the applicability and rationale of generating humanized antibodies from immune rabbits.
viruses, and subsequent infection of Sf9 cells was performed according to the manufacturer's recommendations. Recombinant protein was purified from cell extracts as described (11) .
Rabbit Immunization-Over a period of 4 to 5 months, 2 rabbits from the New Zealand White strain were treated with 3 subcutaneous injections of 10 6 LIM1215 cells followed by 3 subcutaneous injections of 1 g of recombinant human A33 antigen in a 1-ml emulsion of Ribi adjuvant in PBS (Ribi Immunochem Research, Hamilton, MT). Antisera from the immune animals was analyzed for binding to recombinant human A33 antigen by ELISA using alkaline phosphatase-conjugated goat antirabbit Fc polyclonal antibodies (Cappel, West Chester, PA) as secondary antibodies. Five days after the final boost, spleen and bone marrow from 1 leg were harvested and used for total RNA preparation with TRI-REAGENT from Molecular Research Center (Cincinnati, OH). First-strand cDNA was synthesized using the Superscript Preamplification System for First Strand cDNA Synthesis kit with oligo(dT) priming (Life Technologies, Inc.).
Rabbit Antibody Library-The first-strand cDNAs from each rabbit were subjected to separate 35-cycle polymerase chain reactions using Perkin-Elmer AmpliTaq DNA polymerase (Roche Molecular Systems, Brunchburg, NY) and 10 primer combinations for the amplification of rabbit V L (9 ϫ V and 1 ϫ V ) coding sequences and 4 combinations for the amplification of rabbit V H coding sequences (Table I ). The antisense primers consist of a hybrid rabbit/human sequence designed for the fusion of rabbit V L and V H coding sequences to human C and C H 1 coding sequences, respectively. Human C and C H 1 coding sequences were amplified from a pComb3H-compatible expression vector (3) that contained the sequence of a human Fab directed to tetanus toxoid (12) using the primer combination HKC-F (5-ACTGTGGCTGCACCATCTG-TC-3Ј)/lead-B (5ЈGCCATGGCTGGTTGGGCAGC-3Ј) and HIgGCH1-F (5Ј-GCCTCCACCAAGGGCCCATCGGTC-3Ј)/dpseq (5Ј-AGAAGCGTA-GTCCGGAACGTC-3Ј), respectively. The antisense primer lead-B hybridizes to a sequence upstream of the Fd fragment coding sequence and is used to amplify the C coding sequence together with the sequence intervening LC and Fd fragment coding sequences in phagemid vector pComb3H (3) . Based on this strategy, the chimeric rabbit/human LC and Fd fragment coding sequences are assembled and fused by 2 sequential overlap extension polymerase chain reaction steps. In the first step, rabbit V L and human C are fused using the primer combination RSC-F (5Ј-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCG-GCCGAGCTC-3Ј)/lead-B and rabbit V H and human C H 1 are fused using the primer combination lead-VH (5-GCTGCCCAACCAGCCATGGCC-3Ј) and dp-EX (5Ј-GAGGAGGAGGAGGAGGAGAGAAGCGTAGTCCG-GAACGTC-3Ј). In the second step, the assembled chimeric LC and Fd fragment coding sequences are fused using the flanking primers RSC-F and dp-EX. Only LC and Fd fragment coding sequences derived from the same animal were combined. The final construct was cloned into phagemid vector pComb3H using 2 asymmetric SfiI sites (3), yielding a complexity of 2 ϫ 10 7 independent transformants. The phage library displaying the chimeric rabbit/human Fab was panned against immobilized recombinant human A33 antigen using 200 ng of protein in 25 l of TBS for coating on 1 well of a Costar number 3690 96-well plate, 0.05% (v/v) Tween 20 in TBS for washing, and 10 mg/ml trypsin (Difco) in TBS for elution. Trypsinization was for 30 min at 37°C. The washing steps were increased from 5 in the first round to 10 in the second round and 15 in the third and fourth round. A round of panning defines a sequence of binding of the phage to the antigen, removal of unspecific binders, and elution of specific binders followed by their reamplification in Escherichia coli. Indicative of a successful selection, the output numbers strongly increased after the third and fourth round. The output phage pool of each round was monitored by phage ELISA using horseradish peroxidase-conjugated sheep anti-M13 phage polyclonal antibodies (Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom) as secondary antibodies. An increasing signal above background from round to round was noted. Fourty clones from the final output were grown and induced with 1 mM isopropyl-␤-D-thiogalactopyransoside. Supernatants were tested for binding to immobilized recombinant human A33 antigen by ELISA using alkaline phosphataseconjugated goat anti-human F(abЈ) 2 polyclonal antibodies (Pierce, Rockford, IL) as secondary antibody. All clones gave a strong signal above background and were further analyzed by DNA fingerprinting. For this, phagemids were isolated, Fab coding sequences amplified using the flanking primers ompseq (5Ј-AAGACAGCTATCGCGATTG-CAG-3Ј) and gback (5Ј-GCCCCCTTATTAGCGTTTGCCATC-3Ј), and digested with the 4-base pair cutter BstOI. Three different, although highly similar, fingerprints were obtained. Two of them, rabbit clones 1 and 2, were found in 13 and 26 clones, respectively. The third rabbit clone (3) was represented only once. The sequence of the variable domains of heavy and light chain of clones 1, 2, and 3 was determined by DNA sequencing using the primers newpelseq (5Ј-CTATTGCCTAC-GGCAGCCGCTG-3Ј) and ompseq, respectively. Rabbit antibody sequences have been submitted to GenBank™ under accession numbers AF 245498 -245503.
Humanized Antibody Library-Human germ-line V L and V H sequences with the highest degree of homology with the corresponding rabbit sequences were identified from the VBASE Directory of Human V Gene Sequences by amino acid sequence alignment. The identified human sequences were diversified at positions that are potentially involved in antigen binding and used as frameworks for the grafting of the 6 rabbit CDRs as defined by Kabat et al. (13) . Overlapping oligonucleotides were designed accordingly, synthesized, and assembled to synthetic V L and V H coding sequences in 2 sequential 10-cycle polymerase chain reaction steps using the Expand High Fidelity PCR System (Roche Molecular Systems). Using the same procedure as described for the generation of the rabbit antibody library, the synthetic V L and V H coding sequences were fused to human C and C H 1 coding sequences, respectively, and the resulting humanized light chain and Fd fragment coding sequences were assembled. The final construct was SfiI cloned into a variant of pComb3H in which the ampicillin resistance gene had been replaced by a chloramphenicol resistance. This prevents potential contaminations with phage derived from the rabbit antibody libraries. The resulting library with a theoretical complexity of only 256 consisted of 1 ϫ 10 7 independent transformants and was panned against immobilized recombinant human A33 antigen essentially as described for the screening of the rabbit antibody library but under more stringent conditions. The amount of antigen was decreased from 100 ng in the first and second round to 50 ng in the third and fourth round and 25 ng in the fifth and sixth round. Ten washing steps with 0.5% (v/v) Tween 20 in TBS were performed for each of the 6 rounds. Round 3 and 4 as well as 5 and 6 were linked without phage amplification. For this, phage from round 3 and 5 were eluted by adding 50 l of 100 mM HCl glycine (pH 2.2), incubated for 10 min at room temperature, collected, neutralized with 3 l of 2 M Tris base and 50 l of 1% (w/v) bovine serum albumin in TBS, and directly subjected to another round of panning. Phage from rounds 1, 2, 4, and 6 were eluted by trypsinization as described before. Out of 70 clones from the final output that were analyzed by ELISA and all found to be positive, 24 clones were further analyzed by DNA sequencing as described before.
The following oligonucleotides were used for humanization, L denotes primers for the V L assembly, H denotes primers for the V H assembly (r ϭ A or G; S ϭ G or C; W ϭ A or T): L1, 5Ј-GAGCTCCA-GATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG-AGTCACCATCACTTGCCTGGCCAGTGAGTTCCTTTTTAATGGTGT-ATCC-3Ј; L2, 5Ј-AGATGGGACCCCAGATTCTAAATTGGATGCACCA-TAGATCAGGARCTTAGGARCTTTCCCTGGTTTCTGCTGATACCAG-GATACACCATTAAAAAGGAACTC-3Ј; L3, 5Ј-AATTTAGAATCTGGG-GTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGATTWCAC-TCTCACCATCAGCAGCCTGCAGSCTGAAGATGTTGCAACT-3Ј; L4, 5Ј-TTTGATCTCCACCTTGGTCCCTCCGCCGAAAGTCAAACCACTA-CTACCACTATAACCGCCTAGACAGTAATAAGTTGCAACATCTTCA-GSCTGCAG-3Ј; L flank sense, 5Ј-GAGGAGGAGGAGGAGGGCCCAG-GCGGCCGAGCTCCAGATGACCCAGTCTCCA-3Ј; L antisense flank, 5Ј-GACAGATGGTGCAGCCACAGTTCGTTTGATCTCCACCTTGGTC-CCTCC-3Ј; H1, 5Ј-GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCT-GGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTG-GA-3Ј; H2A, 5Ј-CCAGCTAATGCCATAGTGACTGAAGGTGAATCCA-GAGGCTGCACAGGAGAGTCT-3Ј; H2B, 5Ј-CCAGCTAATGCCATAG-TGACTGAAGTCGATTCCAGAGGCTGCACAGGAGAGTCT-3Ј; H3, 5Ј-TTCAGTCACTATGGCATTAGCTGGGTCCGCCAGGCTCCAGGGAA-GGGGCTGGAGTGGGTCGCCTACATTTATCCTAATTATGGGAGTG-TAGACTACGCGAGC-3Ј; H4A, 5Ј-GTTCATTTGCAGATACASTGAGT-TCTTGGCGTTGTCTCTGGAGATGGTGAATCGGCCATTCACGCTG-CTCGCGTAGTCTACACTCCCATA-3Ј; H4B, 5Ј-GTTCATTTGCAGAT-ACASTGAGTTCTGGGCGTTGTCGAGGGAGATGGTGAATCGGCCA-TTCACGCTGCTCGCGTAGTCTACACTCCCATA-3Ј; H5, 5Ј-AACTCA-STGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGT-ATATTWCTGTGCGAGAGATCGGGGTTATTATTCTGGTAGT-3Ј; H6, 5Ј-TGAGGAGACGGTGACCAGGGTGCCCTGGCCCCAGAGATCCAA-CCGAGTCCCCCTACTACCAGAATAATAACCCCGATC-3Ј; H flank sense, 5Ј-GCTGCCCAACCAGCCATGGCCGAGGTGCAGCTGGTGGA-GTCTGGGGGA-3Ј; H flank antisense, 5Ј-GACCGATGGGCCCTTGG-TGGAGGCTGAGGAGACGGTGACCAGGGTGCC-3Ј.
Fab Preparation-Soluble Fab from rabbit clones 1 and 2 and humanized clones A to F were produced in E. coli strain Xl1-Blue using gene III fragment-depleted pComb3H as expression vector (3). Fab were purified from concentrated supernatants and from sonicated lysates of overnight 1-liter flask cultures induced with 1 mM isopropyl-␤-D-thiogalactopyransoside by affinity chromatography using a 5-ml Protein G HiTrap column (Amersham Pharmacia Biotech) attached to an fast protein liquid chromatography system (Amersham Pharmacia Biotech). PBS was used as equilibration and washing buffer and 0.5 M acetic acid for elution. Eluted fractions were neutralized immediately using 0.5 volumes of 1 M Tris-HCl (pH 9.0), pooled, concentrated, and brought into PBS. Quality was analyzed by SDS-PAGE followed by Coomassie Blue staining, quantity by measuring the optical density at 280 nm using an Eppendorf BioPhotometer (Hamburg, Germany).
Surface Plasmon Resonance-Surface plasmon resonance for the determination of association (k on ) and dissociation (k off ) rate constants for binding of rabbit and humanized Fab to recombinant human A33 antigen was performed on a Biacore instrument (Biacore AB, Uppsala, Sweden). A CM5 sensor chip (Biacore AB) was activated for immobilization with N-hydroxysuccinimide and N-ethyl-NЈ-(3-dimethylaminopropyl)carbodiimide according to the methods outlined by the supplier. Recombinant human A33 antigen was coupled at a low density to the surface by injection of 30 to 40 l of a 1 ng/l sample in 10 mM sodium acetate (pH 3.5). Approximately 500 resonance units were immobilized. Subsequently, the sensor chip was deactivated with 1 M ethanolamine hydrochloride (pH 8.5). Binding of Fab to immobilized A33 antigen was studied by injection of Fab at 5 different concentrations ranging from 75 to 200 nM. PBS was used as the running buffer. The sensor chip was regenerated with 20 mM HCl and remained active for at least 50 measurements. The k on and k off values were calculated using Biacore AB evaluation software. The equilibrium dissociation constant K d was calculated from k off /k on . Data obtained from different sensor chips revealed a high consistency and were further validated as described (19) .
Western Blotting-Triton X-100 (0.3% (v/v) in PBS, pH 7.5) lysates of human colon cancer cell lines were resolved by SDS-PAGE under reducing (5% (v/v) ␤-mercaptoethanol) and nonreducing conditions. Proteins were blotted to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford, MA) and incubated with 0.5 g/ml Fab followed by alkaline phosphatase-conjugated goat anti-human F(abЈ) 2 polyclonal antibodies (Pierce). Specific binding was visualized by chemiluminescence (Tropix, Bedford, MA).
Flow Cytometry-Flow cytometry was performed using a FACSscan instrument from Becton-Dickinson (Franklin Lakes, NJ). For each determination, 1 ϫ 10 4 cells were analyzed. Indirect immunofluorescence staining was achieved with 2 g/ml Fab in 1% (w/v) bovine serum albumin, 25 mM Hepes, 0.05% (w/v) sodium azide in PBS. A 1:100 dilution of fluorescein isithiocyanate-conjugated donkey anti-human F(abЈ) 2 polyclonal antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) was used for detection. Incubation with primary antibodies was for 1 h, with secondary antibodies for 30 min at room temperature.
Immunohistochemistry-All immunochemical stainings were done on snap-frozen tissue samples, embedded in O.C.T. compound (Tissue Tek, Torrance, CA). 5-m cuts (HM503 cryostat, Zeiss, Walldorf, Germany) were mounted on slides for immunohistochemistry (Superfrost Plus, Fisher Scientific, Pittsburgh, PA). Serial sections were used, so as to compare staining results of the different antibody preparations. After cutting, the slides were fixed in cold acetone for 10 min and then air dried. Reactivity of the humanized Fab was analyzed using the colon cancer cell line SW1222 xenografted into nude mice. A working concentration of Fab (1 g/ml) was established by titering. The humanized Fab was detected by biotinylated goat-anti human F(ab) 2 polyclonal antibodies (1:200; Vector, Burlingame, CA) and an avidin-biotin complex system (ABC/Elite kit, Vector). Diaminobenzidine tetrahydrochloride (Biogenex, San Ramon, CA) was used as a chromogen. Reactivity of the humanized Fab was also evaluated in human colonic adenocarcinoma samples. In order to prevent immunoreactivity of endogenous human immunoglobulin, a special technique for the detection of humanized Fab was utilized. Prior addition to tissue, the humanized Fab (1 g/ml) was incubated with biotinylated goat-anti human F(ab) 2 polyclonal antibodies in a test tube. The optimal ratio of humanized Fab to secondary antibody was determined in separate titration assays. Incubation of humanized Fab and secondary antibody was done at room temperature for 1 h and followed by an addition of human serum in order to block the activity of unbound secondary antibody. Again, the optimal ratio of human serum to secondary antibody was determined in separate titration assays.
RESULTS
Our strategy for the generation and humanization of rabbit antibodies directed to human A33 antigen is outlined in Fig. 1 .
Two rabbits were immunized with the human colon cancer cell line LIM1215 which expresses large amounts of the A33 antigen. A LIM1215 cDNA library had been used to clone the cDNA for human A33 antigen (8) . The initial immunization and 2 boosts elicited a weak immune response against recombinant human A33 antigen as revealed by the analysis of the rabbit sera by ELISA (data not shown). Both rabbits were further boosted with recombinant human A33 antigen derived from a baculovirus expression system. A strong immune response against recombinant human A33 antigen in sera from both rabbits resulted (data not shown). Our sequential cell and protein immunization strategy aimed at targeting the humoral immune response to native epitopes of the protein that are accessible at the cell surface.
A rabbit antibody library displayed on phage was generated as follows. RNA was isolated from bone marrow and spleen of the immune rabbits, retro-transcribed, and V L and V H coding sequences were amplified using a variety of primer combinations designed to amplify most of the known rabbit antibody sequences (Table I ). The primer combinations used here extend the primer sets reported previously (14 -16) . Importantly, the rabbit antibody library was based on a chimeric Fab format. Variable domains from rabbit light and heavy chains were fused to the corresponding human constant domains. The use of human constant domains suggested several advantages. First, while antigen binding is confined to the variable domains and, thus, is not expected to be influenced by constant domain swapping, the human constant domains confer established and standardized detection and purification means on Fab derived from multiple species. Second, the use of human constant regions was found to improve the E. coli expression level of Fab (17, 18) . Lastly, a Fab with human constant domains is already partially humanized and can be readily channeled into recently reported strategies for complete humanization (19) .
The phage library displaying chimeric rabbit/human Fab was selected by panning against immobilized recombinant human A33 antigen. Among 40 selected clones that demonstrated strong reactivity in ELISA on immobilized recombinant human A33 antigen, only 3 distinct sequences were identified (Fig. 2) . Data bank screening revealed that the sequences corresponding to the variable domains were rabbit sequences. The clones with distinct sequences were designated rabbit clones 1 to 3. Rabbit clones 1 and 2 shared identical V coding sequences and 90% identical V H coding sequences. Rabbit clone 3 consisted of a V coding sequence with 90% identity to rabbit clones 1 and 2 and shared an identical V H coding sequence with rabbit clone 3. The high similarity of the sequences included the hypervariable VDJ and VJ joint regions HCDR3 and LCDR3. Thus, it is likely that all the selected sequences originated from 1 B cell clone in 1 of the 2 rabbits that had undergone somatic diversification.
Rabbit clones 1 and 2 were produced as soluble Fab in E. coli and purified by protein G affinity chromatography (Fig. 3) . Analysis by flow cytometry revealed that both Fab specifically bound to human colon cancer cells expressing native human A33 antigen (Fig. 4) . Binding of the Fab to human A33 antigen was found to be very strong with affinities in the 1 nM range as determined by surface plasmon resonance using a Biacore instrument. Rabbit clones 1 and 2 gave K d values of 390 pM and 1.6 nM, respectively (Fig. 5, Table III ). While both a higher association and a slower dissociation rate constant contributed to the higher affinity of rabbit clone 1, rabbit clone 2 gave consistently higher expression yields in E. coli. Considering the fact that the majority of selected clones contained the rabbit clone 2 sequence, it can be assumed that the higher expression level of rabbit clone 2 led to its preferential selection despite the higher affinity of rabbit clone 1.
As a further step in the generation of therapeutic antibodies directed to human A33 antigen, the selected rabbit variable domains were humanized. We used a humanization strategy that combines CDR grafting with framework fine tuning by phage display. This type of strategy has been used for the humanization of mouse antibodies (20, 21) . The selected rabbit sequences were first aligned with human V and J genes. The selected rabbit V H sequence was found to be most homologous to the human V gene DP-77/3-21 from the V H 3 family and human J gene J H 1. The selected rabbit V sequence was found to be most homologous with the human V gene DPK-4/A20 from the V 1 family and human J gene J 4. These human sequences not only gave the best alignment with the selected rabbit sequences, but are frequently found in the human antibody repertoire in vivo (22) and are highly related to human V genes DP-47/3-23 and DPK-9/O 2 whose frameworks have been used for a number of mouse antibody humanizations and have given high expression yields in E. coli (23) . In fact, pairs of V H 3 family heavy chains and V 1 family light chains are the most frequent combinations found in native human antibodies (24) . Thus, this framework combination is expected to be non-immunogenic in humans. The CDR sequences of rabbit clone 2 were chosen because of the higher expression level of this clone. The 6 rabbit CDR sequences, 3 from each variable domain as defined by Kabat et al. (13) , were grafted into the appropriate human framework sequences. For further humanization, tryptophan at position 62 in the rabbit HCDR2 was converted to serine. For framework fine tuning, residues at 6 positions in the human V H framework sequences and residues at 4 positions in the human V framework sequences were diversified as shown in Table II . These residues were chosen out of a set of key framework residues that are known to be involved in antigen binding, either indirectly, by supporting the confirmation of the CDR loops, or directly, by contacting the antigen (25) . Key framework residues of rodent monoclonal antibodies have been identified structurally by crystallization and molecular modeling as well as empirically by antibody humanization. No such data are available for rabbit monoclonal antibodies. However, the similarity of the primary structure of rabbit antibodies with rodent antibodies (13) makes an analogous set of key framework residues likely. From this set, 10 positions that differed between the rabbit and the human frameworks were identified. These positions were then diversified to allow the selection of basically either the rabbit or the human sequence (Table II) . Position 43 in framework 2 of V L was diversified to allow the selection of either human residue alanine or valine, reflecting the natural diversity of this position in light chains of the V 1 family (13) .
The phage library displaying Fab with a diversified human framework sequence and rabbit CDR sequences was selected by panning against immobilized recombinant human A33 antigen using highly stringent conditions (see "Experimental Procedures"). All selected clones demonstrated strong reactivity in ELISA on immobilized recombinant human A33 antigen. The sequences of 6 selected clones, designated as humanized clones A-F, are given in Fig. 2 . These clones reflect the diversity found in 24 clones that were sequenced. A consensus sequence was found for the diversified framework of V H . Positions 27 and 28 in framework 1 and positions 71 and 75 in framework 3 were found to contain the original rabbit residues isoleucine, aspartic acid, leucine, and glutamine, respectively, in 16 out of 24 clones. While 3 clones contained the human residues phenylalanine and threonine at positions 27 and 28, respectively, none of the clones contained the human residues arginine and lysine at positions 71 and 75, respectively. Interestingly, 2 of the diversified positions were found to contain mutations, i.e. residues that were not included in the diversification. Both mutations were due to a single point mutation that was probably generated by misincorporation during oligonucleotide synthesis or assembly. A glycine at position 28 was found in 3 clones including clones B and F (Fig. 2) . A phenylalanine at position 71 was found in 2 different clones, A and E (Fig. 2) . Most notably, these 5 clones containing the mutations demonstrated the strongest reactivity in ELISA. The remaining 2 positions that were diversified in the framework of V H , i.e. positions 78 and 91 in framework 3, did not give a significant consensus sequence but reflected a rather random selection of either the human or the rabbit residue. A similar result was obtained in the framework of V L at positions 43 and 46 in framework 2 and position 71 in framework 3. The human proline residue at diversified position 80 of framework 3 of V L was found in 18 out of 24 clones including the 5 mutated clones that demonstrated the strongest reactivity in ELISA. The consensus sequence selected at 5 out of 10 diversified positions with a preference of the rabbit sequence at 4 positions demonstrates the potency of the framework fine tuning approach. The fact that further mutations were found in diversified but not in constant positions supporting our set of key framework residues. Considering the potential immunogenicity of rabbit residues in a human framework, we analyzed the natural diversity of the human framework using the Kabat data base. This analysis revealed that all 10 diversified positions are naturally diverse. In fact, only 2 positions in our framework diversification yielded residues that have not been found at these positions in human frameworks. These are aspartic acid and glycine at position 28 in framework 1 of V H and leucine and phenylalanine at position 71 in framework 3 of V H . In a procedure termed resurfacing mouse antibodies have been humanized by just replacing a small set of surface accessible residues (26, 27) . This was based on the suggestion that the humanization of surface accessible residues of a mouse antibody would decrease its immunogenicity (28) . The probability of a human framework residue to be exposed at the antibody surface has been determined by comparing three-dimensional structures of human antibodies (28, 29) . Among our 10 diversified framework residues, only 3 positions are likely to be exposed. These are position 80 of V L and positions 28 and 75 of V H (Table II) . From these only position 28 of V H yielded potentially immunogenic residues as detailed above.
Humanized clones A-F include 4 of the 5 mutated clones (A, B, E, and F) as well as 2 additionally selected clones (C and D) that demonstrated weaker reactivity in ELISA and were included for further characterization for comparison (Fig. 2) . All 6 clones were produced as soluble Fab by E. coli expression and purified by protein G affinity chromatography (Fig. 3) . The recovered yields of Fab ranged from 0.5 to 2 mg per 1-liter shake flask culture. The affinity of each of the humanized Fab was measured by surface plasmon resonance using a Biacore instrument (Table III) . Humanized clone B (K d ϭ 1.7 nM) demonstrated the highest affinity, matching that of the parental rabbit clone 2 (K d ϭ 1.6 nM). The other mutated humanized clones A, E, and F had slightly lower affinities, while the unmutated humanized clones C and D gave the lowest affinities as anticipated based on their ELISA reactivity. The mutations were found to affect both association and dissociation rate constants. The dissociation rate constants of all 4 mutated humanized clones A, B, E, and F were found to be very similar, that is about 2-fold higher compared with parental rabbit clone 2 and about 3-fold lower compared with unmutated humanized clones C and D. Interestingly, humanized clones B and F revealed the highest association rate constants indicating that the substitution of the surface accessible and negatively charged residue aspartic acid by glycine at position 28 of V H improves the association rate.
Analysis by flow cytometry revealed that the 6 selected humanized Fab bound specifically to human colon cancer cells expressing native human A33 antigen (Fig. 4) . This result was confirmed with a rosetting assay in which surface bound humanized Fab were detected by rabbit anti-human F(abЈ) 2 polyclonal antibodies followed by adherence of protein A-coated human red blood cells to human colon cancer cells expressing native human A33 antigen (data not shown). Cell lines that do not express human A33 antigen were negative in both assays ( Fig. 4 ; data not shown). The 4 mutated clones A, B, E, and F demonstrated the strongest reactivity in flow cytometry and rosetting assays. The differences between the humanized clones were found to correlate with their differences in affinity to immobilized recombinant human A33 antigen. The humanized Fab were further analyzed for reactivity with human A33 antigen extracted from colon cancer cell lines by Western blotting. As shown for humanized clone B (Fig. 6) , the humanized Fab strongly reacted with a band of about 43 kDa under nonreducing conditions. No reactivity was observed using reducing conditions (data not shown), suggesting the recognition of a conformational epitope on human A33 antigen (30) . Taken together, these results demonstrate that the selected humanized antibodies bind to a native epitope on human A33 antigen that is fully accessible on the cell surface.
In order to evaluate the selectivity of the humanized Fab in an independent system of higher complexity, their reactivity with tumor tissue sections was analyzed by immunohistochem- istry. As shown for humanized clone B, the humanized Fab reacted strongly with xenografts of the human colon cancer cell line SW1222 grown in nude mice (Fig. 7, A and B) . The humanized Fab revealed immunoreactivity similar to the mouse monoclonal antibody A33 with an intense staining of dysplastic glandular structures in tissue sections of human colon adenocarcinoma after blocking endogenous human immunoglobulins (Fig. 7, C and D) . A comparison of corresponding tissue sections stained with the full blocking step and stained without blocking of the endogenous human immunoglobulins illustrates the amount of internal reactivity (Fig. 7F ) and its complete blocking (Fig. 7E) .
DISCUSSION
Antibody engineering technology has facilitated the generation of antibodies to virtually any antigen of interest as well as their improvement in terms of affinity, specificity, and immunogenicity (2, 31) . The generation of human or humanized antibodies to human antigens is of particular interest for the treatment of a variety of diseases. Here we report a new route to therapeutically relevant humanized antibodies. Using phage display, we selected and humanized antibodies from rabbits immunized with a human antigen.
The rabbit Ig gene repertoire is well characterized (32) . This has allowed the generation of combinatorial rabbit antibody libraries displayed on phage whose screening resulted in the selection of rabbit monoclonal antibodies (14 -16) . While the generation of rabbit monoclonal antibodies by hybridoma technology has also been reported (33) , the phage display approach with its inherent linkage of phenotype and genotype provides ready access to antibody sequences and facilitates further in vitro optimizations such as humanization or affinity maturation.
Compared with the other existing sources of human or humanized antibodies, immune rabbits are an attractive alternative for several reasons. First, humanized antibodies from immune rabbits extend the accessible epitope repertoire of a given antigen. Epitopes that are not immunogenic in mice, a species from which the vast majority of monoclonal antibodies to human antigens has been generated, might be immunogenic in rabbits. This is of particular interest for the development of therapeutic human antibodies that are evaluated in mouse models and are required to recognize both the human antigen and its mouse homologue. In contrast, humanized antibodies that are derived from immune mice, either indirectly through humanization (e.g. Ref. 19) or directly through transgenic mice containing human Ig loci (34) , are negatively selected against epitopes displayed by the mouse homologue. Second, in contrast to human antibodies derived from large naive combinatorial antibody libraries that are selected in vitro (35) , humanized antibodies derived from immune animals have been subjected to in vivo selection and, thus, are more likely to recognize a given antigen selectively. Lastly, as we demonstrate here for the first time, rabbit antibodies can be converted to humanized antibodies that retain both high specificity and affinity to the antigen.
Using Fab display we selected rabbit antibodies with dissociation constants as low as 390 pM. In contrast, rabbit antibodies selected by scFv display revealed 1 to 2 orders of magnitude weaker affinity (14, 16) . While different antigens as well as different immunization schedules are likely to contribute to these differences, Fab display in general may result in the selection of antibodies with higher affinity. This is based on the fact that Fab are displayed monovalently at the phage surface and are selected based on affinity and expression, whereas the selection of scFv is also influenced by avidity due to their tendency to dimerize or form higher order aggregates (2, 3). As a result, antibodies selected as scFv do not generally bind their antigen well when they are converted in the Fab format. In contrast, we found that the opposite conversion from Fab to scFv format yielded scFv with high apparent affinity, for instance, in the case of humanized clone B which is described here (data not shown). Fab are also readily convertible to whole antibody formats by simple fusion with Fc coding sequences which does not affect the antigen-binding site. In summary, selections based on the Fab format generate antibodies that are well suited for therapeutical evaluation in multiple formats.
We chose human A33 antigen as target for the development of humanized antibodies from immune rabbits. Human A33 antigen has been established as a target for radioimmunotherapy of colon cancer in phase I and II clinical trials with 131 Iand 125 I-labeled mouse monoclonal antibody A33 (5-7). Antitumor effects were demonstrated in these studies despite the fact that only a single dose could be administered due to development of a human anti-mouse antibody response. A33 was retained for prolonged periods (up to 6 weeks) in tumors but was cleared rapidly from normal colon (5-6 days). In fact, bone marrow suppression was the dose-limiting toxicity in the radioimmunotherapy trials and no normal colon toxicity was observed. To make repeated administrations feasible, A33 was humanized by CDR grafting (36) and evaluated in phase I and II clinical trials. While these studies confirmed antitumor effects, a number of patients developed a human anti-human antibody response after several administrations, forcing the termination of the treatment. 2 Analysis of sera from the patients revealed evidence for an anti-idiotypic immune response, i.e. the sera contained antibodies that recognized the antigenbinding site of humanized antibody A33. 3 Administration of an equally potent humanized antibody that is unreactive to the anti-idiotypic immune response generated by humanized antibody A33 would allow therapy to continue.
The humanized antibodies described here compare favorably to the previously described humanized antibody A33. They were found to recognize a cell surface epitope of the A33 antigen with a specificity as high as mouse and humanized antibody A33. The monovalent affinity of humanized clone B is 5-10-fold higher than the monovalent affinity reported for mouse and humanized antibody A33 (36, 37) . Using surface plasmon resonance (data not shown), we further found that the humanized antibodies described here (i) bind to an epitope on the A33 antigen distinct from the epitope recognized by mouse and humanized antibody A33, and (ii) are not recognized by sera from patients who had developed an anti-idiotypic immune response after repeated treatment with humanized antibody A33. Thus, regarding therapeutic application, our humanized antibodies derived from the rabbit antibody repertoire complement humanized antibody A33 derived from the mouse antibody repertoire. Based on these findings, immune rabbits may be an important source for the generation of therapeutic human antibodies.
